The present disclosure relates to the use MNK specific inhibitors to inhibit immunosuppression components such as immune checkpoint proteins PD 1 PD L1 LAG3 and/or immunosuppressive cytokines such as IL 10 in order to inhibit or release immune suppression in certain diseases such as cancer and infectious disease.